<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314723/" ref="ordinalpos=891&amp;ncbi_uid=4751967&amp;link_uid=PMC3314723" image-link="/pmc/articles/PMC3314723/figure/F3/" class="imagepopup">Figure 3. Effects of HIF-1α silencing and suppression of EPO <span class="highlight" style="background-color:">signaling</span> on cell viability.  From: Pyruvate Protects Brain Against Ischemia-Reperfusion Injury by Activating Erythropoietin <span class="highlight" style="background-color:">Signaling</span> <span class="highlight" style="background-color:">Pathway</span>. </a></div><br /><div class="p4l_captionBody"><b>A)</b> HIF-1α siRNA blunted HIF-1α expression in HT22 neuronal cells. <b>B)</b> HIF-1α silencing abrogated pyruvate protection of hypoxic, glucose-deprived cells (*P&lt;0.05 vs. Normoxia). <b>C, D)</b> Interruption of EPO pathway with soluble EPOR dampened pyruvate-induced protection in HT22 cells. *P&lt;0.05 vs. Normoxia; †P&lt; 0.05 vs. Control; ‡P&lt; 0.05 vs. Pyruvate.</div></div>